Benefits and Pitfalls of Plasmin Derivatives Application for Thrombolysis: A Narrative Review
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | American Journal of Biomedical Science and Research |
| MU Faculty or unit | |
| Citation | |
| web | https://biomedgrid.com/pdf/AJBSR.MS.ID.003101.pdf |
| Doi | http://dx.doi.org/10.34297/AJBSR.2024.23.003101 |
| Keywords | Myocardial infarction; Ischemic stroke; Thrombosis; Thrombolysis; Thrombolytics; Plasmin(ogen); Alteplase; Liposome |
| Description | Cardio- and cerebrovascular thrombosis is a serious pathology with the highest lethality and disability rates in the world. The current thrombolytic therapy is mainly based on plasminogen activators, such as streptokinase, urokinase and tissue plasminogen activator. As soon as their target is ad hoc plasminogen activation, an addressed plasmin(ogen) delivery to a clot could have at least the same efficiency. Here we present in a form of narrative review thrombolytic potential of plasmin(ogen) and its derivatives, which in some experiments outperformed approved plasminogen activators. We believe that these factors will find their niches in clinical thrombolytic therapy in the near future. |
| Related projects: |